The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial
Abstract
Objective: To evaluate the safety of anakinra (a recombinant human interleukin‐1 receptor antagonist) in a large population of patients with rheumatoid arthritis (RA), typical of those seen in clinical practice. Methods: A total of 1,414 patients were randomly assigned to treatment with 100 mg of anakinra or placebo, administered daily by subcutaneous injection. Background medications included disease‐modifying antirheumatic drugs, corticosteroids, and nonsteroidal antiinflammatory drugs, alone or in combination. The primary end point was safety, which was evaluated by adverse events (including infections), discontinuation from study due to adverse events, and death. Results: Safety was evaluated in 1,399 patients (1,116 in the anakinra group and 283 in the placebo group; 15 patients were randomized but did not receive any study drug) during the initial 6‐month, double‐blind, placebo‐controlled phase of this long‐term safety study. Baseline demographics, disease characteristics, and concomitant medications were similar between the 2 groups. The study group included patients with numerous comorbid conditions and a wide range of RA disease activity. Serious adverse events occurred at a similar rate in the anakinra group and the placebo group (7.7% and 7.8%, respectively). Serious infectious episodes were observed more frequently in the anakinra group (2.1% versus 0.4% in the placebo group). The rate of withdrawal due to adverse events was 13.4% in the anakinra group and 9.2% in the placebo group. Conclusion: Results from this large, placebo‐controlled safety study demonstrate that anakinra is safe and well tolerated in a diverse population of patients with RA, including those with comorbid conditions and those using multiple combinations of concomitant therapies. Although the frequency of serious infection was slightly higher in the anakinra group, no infection was attributed to opportunistic microorganisms or resulted in death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Self-citationA Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Self-citationMoreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Self-citationRheumatoid Arthritis: Pathophysiology and Implications for Therapy
Epstein, F. H., & Harris, E. D. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221805 · Cited by 1,551
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Self-citation
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationNew Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation
Ben-Sasson, S. Z., Hu-Li, J., Quiel, J., Cauchetaux, S., Ratner, M., Shapira, I., Dinarello, C. A., & Paul, W. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902745106 · Cited by 568
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., & Tugwell, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007848.pub2 · Cited by 470
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20583 · Cited by 367
Self-citationTherapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 350
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
Anakinra for Rheumatoid Arthritis: A Systematic Review
MERTENS, M., & SINGH, J. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090074 · Cited by 344
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Kuek, A., Hazleman, B. L., & Östör, A. J. K. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.052688 · Cited by 335
Major biological obstacles for persistent cell-based regeneration of articular cartilage
Steinert, A. F., Ghivizzani, S. C., Rethwilm, A., Tuan, R. S., Evans, C. H., & Nöth, U. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2195 · Cited by 321
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
Self-citationIkonomidis, I., Lekakis, J. P., Nikolaou, M., Paraskevaidis, I., Andreadou, I., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P. N., & Kremastinos, D. T. (2008) · Circulation · doi:10.1161/circulationaha.107.731877 · Cited by 307
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Cohen, S. B., Moreland, L. W., Cush, J. J., Greenwald, M. W., Block, S., Shergy, W. J., Hanrahan, P. S., Kraishi, M. M., Patel, A., Sun, G., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016014 · Cited by 305
Self-citationTargeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Lopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Naredo, E., Rodríguez, M., Campos, C., Rodríguez‐heredia, J. M., Medina, J. A., Giner, E., Martínez, O., Toyos, F. J., Ruíz, T., Ros, I., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23529 · Cited by 294
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Furst, D. E. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Kay, J. (2004) · Rheumatology · doi:10.1093/rheumatology/keh201 · Cited by 280
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial
Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., Dinarello, C. A., van der Meer, J. W. M., Rigopoulos, D., & Giamarellos-Bourboulis, E. J. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3903 · Cited by 266
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
DINARELLO, C. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.010 · Cited by 195
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-04
- Volume
- 48
- Issue
- 4
- Pages
- 927-934
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1975501001
- Cited by
- 392
- References
- 30
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.